UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
This observational study will evaluate an assay using a patient’s own biopsy or resected tumor tissue to assess tissue response to various therapeutic agents.
Conditions
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Chordoma
The purpose of this Phase I clinical trial is to evaluate the safety and dosage of tazemetostat in treating children and young adults with relapsed or refractory tumors, including AT/RT and chordoma.
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
This phase III clinical trial will evaluate marizomib in combination with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma.
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
The phase I trial will evaluate the safety and efficacy of nivolumab and ipilimumab before and after surgery in treating children and young adults with recurrent or progressive high grade glioma.
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Ependymoma
Medulloblastoma
The purpose of this Phase I/II clinical trial is to evaluate the dosage, safety and efficacy of pembrolizumab in treating pediatric participants with advanced, relapsed, or refractory malignant solid tumor or lymphoma.
Conditions
Glioma
Astrocytoma
Diffuse astrocytoma (grade II)
Pilocytic astrocytoma (grade I)
Pleomorphic xanthoastrocytoma (grades II-III)
This phase III clinical trial will compare the efficacy of selumetinib compared to standard treatment with carboplatin/vincristine (CV) in patients with NF1-associated low-grade glioma (LGG).
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
This phase III clinical trial will evaluate the efficacy of selumetinib compared to treatment with carboplatin/vincristine (CV) in patients with low-grade glioma (LGG).
Conditions
Glioma
Astrocytoma
Diffuse astrocytoma (grade II)
Oligodendroglioma
This clinical trial evaluates the safety and feasibility of IMA950 (a vaccine-based immunotherapy) in combination with varlilumab (an antibody-based immunotherapy) in patients with newly diagnosed or recurrent low-grade glioma (grade II).
Conditions
Glioma
Astrocytoma
Glioblastoma (grade IV)
Anaplastic astrocytoma (grade III)
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I clinical trial will evaluate the safety, efficacy and clinical activity of BGB-290 in combination with temozolomide, for treating adolescents and young adults with IDH1/2-mutant glioma (grades I-IV).
Conditions
Glioma
Astrocytoma
Diffuse Midline Glioma
Brainstem Glioma
This Phase I clinical trial will assess the safety and preliminary efficacy of delivering nal-IRI (a specialized formulation of irinotecan, a chemotherapy drug) directly into the brain through convection enhanced delivery, in treating children with newly diagnosed DIPG.
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
Ependymoma
Oligodendroglioma
This pilot trial will evaluate an individualized treatment approach for children and young adults with high-grade glioma, using proteomic, transcriptomic, and genomic profiling to provide a personalized treatment plan.
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
This phase II clinical trial will evaluate the efficacy of dabrafenib and trametinib after radiation therapy in children and young adults with BRAF V600 mutant high-grade glioma.